Clinical trials: Liraglutide
Diabetes, Healthy
Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers
This trial is conducted in Europe. The aim of this trial is to compare the exposure of liraglutide in young versus elderly healthy subjects.
- Trial name
- NCT01507337
- Testing
- liraglutide
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease
Fibrosis Lessens After Metabolic Surgery
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia.
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis
- Trial name
- FLAMES (NCT06374875)
- Testing
- Metabolic surgery, Incretin-Based Therapy
- Where
- 22 sites in United States, Brazil and 11 more
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Obesity (Disorder), Child Obesity
Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesity
The aim of the study is to examine the effects of pharmacological treatment for obesity on BMI trajectories and metabolic markers among patients in routine clinical care. A retrospective observational study.
- Trial name
- NCT07304141
- Testing
- Liraglutide 3 mg (Saxenda)
- Where
- Sweden
- Volunteers
- 128 people
- Sponsor
- Göteborg University
Type2Diabetes, ASCVD
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D)…
- Trial name
- PRECIDENTD (NCT05390892)
- Testing
- SGLT2 inhibitor, GLP-1 receptor agonist
- Where
- 36 sites in United States
- Volunteers
- 6,000 people
- Sponsor
- Brigham and Women's Hospital
Type 2 Diabetes Mellitus, Cardiovascular Diseases
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
This study is designed to help patients with type 2 diabetes and their clinicians: (a) identify which glucose lowering medications have the most favorable effects on heart health and other patient-important outcomes, (b) inform…
- Trial name
- ON TARGET DM (NCT05073692)
- Testing
- SU, DPP4, SGLT2i
- Where
- 6 sites in United States
- Volunteers
- 241,981 people
- Sponsor
- Kaiser Permanente
Non-alcoholic Fatty Liver Disease, Obesity
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease
STUDY OBJECTIVE: To explore the clinical efficacy and safety of liraglutide in obesity combined with metabolism-associated fatty liver disease (MAFLD).
- Trial name
- NCT06501326
- Testing
- Liraglutide, Orlistat
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Affiliated Hospital of Nantong University
Acute Myocardial Infarction
Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury
The investigators planned to research the cardioprotective effects of intravenous liraglutide on reperfusion injury.
- Trial name
- NCT02001363
- Testing
- liraglutide (Novo Nordisk, Bagsværd, Denmark)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chen Wei Ren, MD
Type 2 Diabetes
Human Bioequivalence Test of Liraglutide Injection
To evaluate the bioequivalence of The liraglutide injection produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Victoza® produced by Novo Nordisk (China) Pharmaceutical Co., Ltd for single dose in healthy subjects,so…
- Trial name
- NCT05029076
- Testing
- Liraglutide injection, Victoza
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to to investigate if there is a drug-drug interaction between liraglutide and paracetamol (Benuron®) and to investigate the effect of liraglutide on post prandial…
- Trial name
- NCT01517555
- Testing
- liraglutide, paracetamol
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Overweight
Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes
The purpose of this research study is to learn about the effect of Liraglutide, (Victoza®), on the fat surrounding the heart.Excessive amount of the fat around the heart is common in people with type 2 diabetes and can be…
- Conditions
- Type 2 Diabetes, Overweight, Obesity
- Trial name
- NCT02014740
- Testing
- Liraglutide, Metformin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Miami
Diabetes, Healthy
Comparison of Two Liraglutide Formulations in Healthy Subjects
This trial is conducted in Europe. The aim of this trial is to test for bioequivalence of the phase 3a formulation of liraglutide at pH 8.15 (formulation 4) and liraglutide at pH 7.7 (formulation 3).
- Trial name
- NCT01515579
- Testing
- liraglutide
- Where
- Sweden
- Volunteers
- 22 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Incretin-based Drugs and Acute Pancreatitis
The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone or in combination with other anti-diabetic drugs are associated with an increased risk of acute…
- Trial name
- NCT02476760
- Testing
- DPP-4 inhibitors, GLP-1 analogs, Insulins
- Where
- Canada
- Volunteers
- 1,417,914 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Type-2 Diabetes
Liraglutide and Cardio-Metabolic Risk Markers
Incretin-based therapies have shown significant effects beyond those on glucose metabolism. We aim in the present study to evaluate the effects of liraglutide on several cardio-metabolic risk markers.
- Trial name
- NCT01715428
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- University of Palermo
Type 2 Diabetes, Gastric Banding
Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding
The purpose of this study is to determine whether addition of 1 or 2 medicines after gastric banding can improve remission of type 2 diabetes.
- Trial name
- NCT01597531
- Testing
- Liraglutide, Orlistat, Liraglutide + Orlistat
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- East Carolina University
Dyspnea, Quality of Life
Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity
Most research to date on bariatric surgery outcomes has been about metabolic syndrome, a disorder very effectively treated by bariatric surgery.
- Trial name
- NCT05812183
- Testing
- Bariatric surgery, Medical weight loss
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Diabetes Mellitus Type 2, Diastolic Dysfunction
Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients
The purpose of this study is to determine whether liraglutide a GLP-1 analogue are effective in the treatment of diastolic dysfunction in type 2 diabetes patients analyzed by cardiac MRI.
- Conditions
- Diabetes Mellitus Type 2, Diastolic Dysfunction, Cardiac MRI, Myocardial Perfusion
- Trial name
- NCT02655770
- Testing
- Liraglutide
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
This trial is conducted globally (the United States of America excepted). This trial is designed to show the effect of treatment with liraglutide when added to existing glimepiride therapy and to compare this to both glimepiride…
- Trial name
- LEAD-1 (NCT00318422)
- Testing
- liraglutide, rosiglitazone, glimepiride
- Where
- 127 sites in Argentina, Australia and 21 more
- Volunteers
- 1,041 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Overweight
Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes
This is an open-label comparative study in three parallel groups. It is expected that 90 patients and/or healthy volunteers will participate in this biomedical research.
- Trial name
- GLP1 et Goût (NCT02674893)
- Testing
- Liraglutide, Observation alone
- Where
- France
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Type 1 Diabetes
Incretin-based Therapy in Early Diagnosed Type 1 Diabetes
The main objective of the trial is to study whether daily treatment with liraglutide improves insulin secretion and reduces the requirement of exogenous insulin, and whether liraglutide treatment is tolerable and safe in subjects…
- Trial name
- NCT02908087
- Testing
- Victoza® (liraglutide)
- Where
- 4 sites in Finland, Sweden
- Volunteers
- 13 people
- Sponsor
- University of Oulu
Diabetes, Diabetes Mellitus, Type 1
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
This trial is conducted in Africa, Europe and North America. The purpose of the trial is to investigate the efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetes.
- Trial name
- ADJUNCT TWO™ (NCT02098395)
- Testing
- liraglutide
- Where
- 120 sites in United States, Austria and 11 more
- Volunteers
- 835 people
- Sponsor
- Novo Nordisk A/S